Tekla Life Sciences Investors
HQLNYSEFinancial Services● Active
$16.67
$-0.25(-1.48%)
Market Cap$506901360
P/E Ratio—
52W High$18.46
52W Low$12.34
Tekla Life Sciences Investors（HQL）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · HQL · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-09 | 2023-09 | 2022-09 | 2021-09 | 2020-09 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $85.59M | $22.35M | ($0.10M) | $0.06M | $0.12M |
| Depreciation & Amort. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($0.20M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Operations | ($2.32M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Investing Activities | |||||
| Capital Expenditure | ($0.00M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Purchases of Investments | ($314.13M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $339.34M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $25.21M | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | ($31.63M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | ($31.63M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Free Cash Flow | |||||
| Free Cash Flow | ($2.32M) | $0.00M | $0.00M | $0.00M | $0.00M |
| FCF Margin %(computed) | -2.69% | 0.00% | 0.00% | 0.00% | 0.00% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Tekla Life Sciences Investors
关于Tekla Life Sciences Investors（HQL）现金流量表
Tekla Life Sciences Investors 2025财年经营活动现金流($0.00B)，自由现金流($0.00B)（FCF利润率-2.69%），资本支出($0.00B)。
常见问题
HQL · 4 问Tekla Life Sciences Investors 2025财年自由现金流($0.00B)，同比down—%。
HQL free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10